DEFINE Trial: Difference between revisions

	High Density Lipoprotein Microchapters
Home
Patient information
Overview
Historical Perspective
Classification
Physiology
Pathophysiology
Causes Low HDL High HDL
Epidemiology and Demographics
Screening
Natural History, Complications and Prognosis
Diagnosis
HDL Laboratory Test
Treatment
Medical Therapy
Prevention
Future or Investigational Therapies
Clinical Trials
Landmark Trials
List of All Trials
Case Studies
Case #1
DEFINE Trial On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of DEFINE Trial All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on DEFINE Trial
CDC on DEFINE Trial
DEFINE Trial in the news
Blogs on DEFINE Trial
Directions to Hospitals Treating High density lipoprotein
Risk calculators and risk factors for DEFINE Trial

VisualWikitext

Revision as of 12:35, 18 September 2013

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Objective

Timeline

Methods

Results

Conclusion

References

@@ Line 3: / Line 3: @@
 {{CMG}}
-==Overview==
-* Various clinical trials<ref name="pmid19781408">{{cite journal |author=Cannon CP, Dansky HM, Davidson M, ''et al.'' |title=Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib |journal=[[American Heart Journal]] |volume=158 |issue=4 |pages=513–519.e3 |year=2009 |month=October |pmid=19781408 |doi=10.1016/j.ahj.2009.07.028 |url=}}</ref><ref name="pmid18068514">{{cite journal |author=Krishna R, Anderson MS, Bergman AJ, ''et al.'' |title=Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies |journal=[[Lancet]] |volume=370 |issue=9603 |pages=1907–14 |year=2007 |month=December |pmid=18068514 |doi=10.1016/S0140-6736(07)61813-3 |url=}}</ref> showed that [[anacetrapib]] significantly lowers [[LDL]] cholesterol and raises [[HDL]] levels without any increase in [[systolic blood pressure]].
+==Objective==
+==Timeline==
+==Methods==
+==Results==
+==Conclusion==
 ==References==
 {{Reflist|2}}

v t e Lipopedia
Basic Science	Cholesterol • Triglyceride Lipoprotein metabolism and transport Lipoprotein: Chylomicron • Chylomicron remnant • HDL • IDL • LDL • Lipoprotein(a) • VLDL • Lipoprotein-X Apolipoprotein: APOA (1, 2, 4, 5) • APOB ( Apolipoprotein B-48, Apolipoprotein B-100) • APOC (1, 2, 3, 4) • APOD • APOE • APOH • APOJ • APOL • APOM • Apo(a) Lipoprotein receptor: LDL receptor • Soluble low density lipoprotein receptor-related protein (sLRP) • Apolipoprotein E Receptor 2 • Scavenger receptor • Scavenger receptor A • Scavenger receptor B • VLDL receptor Lipoprotein enzymes: Lipoprotein lipase • Lipoprotein-associated phospholipase A2 (Lp-PLA2) • Cholesterylester transfer protein ( Acetyl-CoA C-acyltransferase, Lecithin-cholesterol acyltransferase) • Microsomal triglyceride transfer protein • ABCA1 Genes: Low density lipoprotein receptor gene family • Microsomal triglyceride transfer protein • ABCA1
Lipoprotein Disorders	Lipoprotein disorders Primary lipoprotein disorders: Familial hyperchylomicronemia (Type I) • Familial hypercholesterolemia (Type IIA) • Familial combined hyperlipidemia (Type IIB) • Dysbetalipoproteinemia (Type III) • Primary hypertriglyceridemia (Type IV) • Mixed hyperlipoproteinemia (Type V) Secondary lipoprotein disorders
Abnormal Laboratory Lipid Profile	Low chylomicron • Low chylomicron remnant • Low HDL • Low IDL • Low LDL • Low lipoprotein(a) • Low VLDL High chylomicron • High chylomicron remnant • High HDL • High IDL • High LDL • High Lipoprotein(a) • High VLDL

DEFINE Trial: Difference between revisions

Revision as of 12:35, 18 September 2013

Objective

Timeline

Methods

Results

Conclusion

References

Navigation menu